Merck

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Tuesday, February 27, 2024
International, Pfizer, Operating cost, Growth hormone therapy, Merck, PIN, Note, Health, REACH, COVID-19 testing, Sale, Storefront, Debt-to-GDP ratio, Epstein–Barr virus, COVID-19, GeneDx, OPKO Health, Intellectual property, Modex, Immunity, Ali Baba, Research

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.

Key Points: 
  • MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
    Business highlights from the fourth quarter and subsequent weeks included the following:
    ModeX advanced its antiviral and immune-oncology product pipeline.
  • Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
  • Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
BRAF, PD, Research, International Myeloma Foundation, Sale, Lung cancer, Workforce, Poster, Melanoma, P-value, Clinical trial, ATM, BCMA, Therapy, CCCC, Roche, Completeness, CRC, AACR, Conference, Colorectal cancer, Merck, NHL, Research and development, Cancer, Dexamethasone, Administration, Patient, Finance, Biogen, Pharmaceutical industry

WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2023, as well as recent business updates.

Key Points: 
  • As of February 2024, three escalation cohorts are complete and dose escalation continues with a fourth dose level currently enrolling.
  • In December 2023, C4T and Merck entered into a license and research collaboration to discover and develop degrader antibody conjugates.
  • Net loss per share for the year ended December 31, 2023 was $2.67, compared to $2.62 for the year ended December 31, 2022.
  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2023 were $281.7 million, compared to $337.1 million as of December 31, 2022.

Kneat Announces Record Revenue for Fourth Quarter and Full Year 2023

Retrieved on: 
Wednesday, February 21, 2024
IPF, Revenue stream, Merck, Customer success, NRR, OTC, Interest, TSX, Investment, Adjustment, KSI, ARR, Software as a service, Organization, Webcast, Support, Global Operations, Colum, Computer, Q&A, Bank statement, Depreciation, Churn, Video game

SaaS revenue for the fourth quarter of 2023 grew 58% to $8.9 million, versus $5.7 million for the fourth quarter of 2022.

Key Points: 
  • SaaS revenue for the fourth quarter of 2023 grew 58% to $8.9 million, versus $5.7 million for the fourth quarter of 2022.
  • Gross margin in the fourth quarter of 2023 was 72%, compared to 63% for the fourth quarter of 2022, and 65% for the third quarter of 2023.
  • EBITDA1 in the fourth quarter of 2023 was ($0.1) million, compared with $2.2 million for the fourth quarter of 2022.
  • Adjusted EBITDA1 in the fourth quarter of 2023 was ($0.4) million, compared with ($1.3) million for the fourth quarter of 2022.

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Retrieved on: 
Tuesday, February 20, 2024
MSD, Infection, Organization, Merck, Merck & Co., AI, Vaccine, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).

Key Points: 
  • COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).
  • Further, we are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase.
  • Using Evaxion's proprietary platform, AI-Immunology™, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues.
  • The conclusion of the antigen discovery and design phases marks a significant milestone for the development of the vaccine candidate, EVX-B3.

Accenture Launches Accenture LearnVantage to Help Clients and Their People Gain Essential Skills and Achieve Greater Business Value in the AI Economy

Retrieved on: 
Tuesday, March 5, 2024
Technology, Software, Networks, Internet, Continuing, Training, Data Management, Education, Artificial Intelligence, MSD, Cloud, Acquisition, Google Cloud, Merck, Amazon Web Services, Multimedia, AI, Gen, Learning, Data science, Vaccine, Skillsoft, Organization, Patient, Udacity, Microsoft, Research, Partnership

View the full release here: https://www.businesswire.com/news/home/20240304559950/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240304559950/en/
    Accenture today announced the launch of Accenture LearnVantage to provide its clients with comprehensive technology learning and training services that will help them reskill and upskill their people in technology, data and AI to reinvent their organizations and achieve greater business value.
  • Accenture LearnVantage will offer tailored technology learning programs; specialized, predesigned technology academies; ecosystem learning certification services; and managed services for a client’s own learning capabilities.
  • LearnVantage also will offer nanodegrees, certified online programs designed to provide users with hands-on experience and industry-relevant skills in specialized fields.
  • “Accenture LearnVantage will help our clients not only advance their business goals but also help their people build the skills they will need for the next waves of technology change.”

Impact Podcast with John Shegerian Announces March’s All-Star Guest Lineup of Sustainability Innovators

Retrieved on: 
Thursday, February 29, 2024
TV and Radio, Podcast, Technology, Professional Services, General Entertainment, Entertainment, Environmental, Social and Governance (ESG), Other Technology, Environment, Hardware, Sustainability, Clorox, Procter, General Motors, Virginity, Albertsons, T-Mobile, Whole Foods Market, Panasonic, LexisNexis, Gensler, UPS, General Mills, PwC, Salesforce, McKinsey & Company, ITT, Electronics, Johnson & Johnson, HP, Gap Inc., Wells Fargo, The Home Depot, Ford, EBay, ESPN, Procter & Gamble, Colgate-Palmolive, FedEx, Professional corporation, Amazon Music, Google Podcasts, The Hershey Company, ESG, JetBlue, Molson Coors, Hertz, BMW, Webby Awards, Accenture, Verizon Communications, Tractor Supply Company, Adobe, Comerica, Merck, Intel, Best Buy, ERI, Kraft Heinz, Dell, IBM, Visa, Texas Instruments, Entrepreneurship, AT&T, KPMG, Music

Impact Podcast with John Shegerian has announced its roster of guests for March, featuring a who’s who of circularity, ESG, sustainability and corporate responsibility all-stars from many of the world’s leading brands.

Key Points: 
  • Impact Podcast with John Shegerian has announced its roster of guests for March, featuring a who’s who of circularity, ESG, sustainability and corporate responsibility all-stars from many of the world’s leading brands.
  • The Webby Award honored show is hosted by John Shegerian, Co-Founder, Chairman and CEO of ERI , the nation’s leading fully integrated IT and electronics asset disposition provider and cybersecurity-focused hardware destruction company.
  • Impact Podcast guests are invited to share with listeners first-hand accounts of how they are able to help make the world a better place on a daily basis.
  • “Our Impact Podcast roster of experts features leaders who work every day to help make our world a better place.

EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits

Retrieved on: 
Thursday, February 29, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Senior, Merck, Quality of life, Merck Serono, Treatment, Disease, Multiple sclerosis, System, Safety, EDSS, Health care, Bawskee 3.5, SDMT, Patient, Employment, Cladribine, Sclerosis, RMS, Tablet, Merck Group, MRI, Pharmaceutical industry

The first presentation examines the stability or improvement in cognitive processing speed over a two-year period, suggesting the potential of MAVENCLAD to maintain or improve cognitive function in patients with highly active RMS.

Key Points: 
  • The first presentation examines the stability or improvement in cognitive processing speed over a two-year period, suggesting the potential of MAVENCLAD to maintain or improve cognitive function in patients with highly active RMS.
  • Additionally, interim findings from year three of the MAGNIFY-MS extension trial underscore the continued efficacy and safety profile of MAVENCLAD, which is consistent with earlier safety data.
  • These data are being presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.
  • The post-hoc analysis from 270 patients showed a clinically meaningful benefit in cognitive processing speed in patients treated with MAVENCLAD.

Antibiotic Drugs Market Analysis Report 2024: Surging Demand, Trends, and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
Health, Pharmaceutical, Pfizer, Urinary tract infection, Merck, USD, GSK, Strategic planning, Cephalosporin, Pneumonia, Prevalence, Merck & Co., Meningitis, Infection, Pharmaceutical industry

The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The report meticulously evaluates the antibiotic drugs industry's landscape, emphasizing the key drug classes such as Cephalosporins, Penicillins, Macrolides, and Fluoroquinolones.
  • This investigation aligns with an increased emphasis on antibiotic stewardship and the urgent need for combating antibiotic resistance globally.
  • The Antibiotic Drugs Market report not only underscores the significant trends and growth drivers but also furnishes a detailed forecast, setting the stage for informed decision-making and strategic planning within the pharmaceutical sector.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MRK, Research, CRL, New Drug Application, Investment, Eisai, Growth, Sale, Parent, Novin, Focal segmental glomerulosclerosis, Streptococcus, LGND, FSGS, Breakthrough therapy, BLA, AED, GAAP, Therapy, NASH, Liver, NDA, Depreciation, Breast cancer, Total, Forecasting, Perampanel, Shanda, Telecanthus, ID, Retirement, PDUFA, Vaccine, Symantec Endpoint Protection, Type 2 diabetes, Safety, VRNA, Molluscum contagiosum, F2, Acquisition, Caregiver, Merck, AASLD, FDA, Telephone, Food, Pneumonia, Income tax, Hepatology, COVID-19, Element, Patient, SPA, Pharmaceutical industry

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

3D Cell Cultures Technologies Report 2024, Featuring Profiles of Leading Market Participants Including Abcam, Agilent Technologies, Corning, Merck, Beckman Coulter and Synvivo - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024
Health, Infectious Diseases, Other Science, Research, Pharmaceutical, Science, Agilent Technologies, Collagen, Cancer, Merck, Regenerative medicine, 2D, Abcam, Drug resistance, Gel, Liver disease, Stem cell, 3D, Growth, Drug discovery, Metastasis, Skin, Cell, HCMI, Safety, COVID-19, Cell biology, Patient, Burns, Biology, Software, Corning Inc., 3D printing

3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.

Key Points: 
  • 3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.
  • 3D cell culture models mimic the 3D structure and cell-cell interactions that are found in real tissues, making them more accurate and predictive than traditional 2D cell culture models.
  • There are a variety of 3D cell culture technologies available, including:
    Scaffold-based 3D cell culture: This approach uses a scaffold to provide a 3D support structure for cells to grow on.
  • Bioprinting: This approach uses a 3D printer to deposit cells and biomaterials layer-by-layer to create complex 3D cell culture models.